FDA expands approval of breast cancer drug Kisqali

The US FDA has expanded the approval of Kisqali - a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, Novartis said. Experts say, the approval would mean that millions of women diagnosed with early-stage breast cancer will now have access to a medication that helps prevent their cancer from coming back.